The aim of this study was to evaluate whether a patented single-channel applicator, which was modified from the traditional tandem applicator and wrapped with an oval-shield alloy around the source channel, has the same clinical efficacy and safety as the standard Fletcher-type applicator in high dose rate ( All but 3 patients were treated with concurrent cisplatin chemotherapy and external beam radiotherapy followed by HDR brachytherapy. The 2-year overall survival, progression-free survival, and locoregional failure-free survival was 80.3%, 77.5%, and 78.9%, respectively, for the Fletcher group, and 86.3%, 82.5%, and 83.8%, respectively, for the single-channel group. The seriousness of acute treatment-related toxicities was similar in the 2 groups. The cumulative rate of late rectal complications of grade 3-4 in the Fletcher group and the single-channel group was 2.8% and 2.5%, respectively. The cumulative rate of grade 3 bladder complications was 2.8% for the Fletcher group and 1.3% for the single-channel group. The preliminary results of our study show that the patented single-channel intracavitary applicator might be able to provide protection for the rectum and bladder and seems to have the same clinical efficacy as the standard Fletcher-type 3-channel applicator in HDR brachytherapy for carcinoma of the cervix. This trial was registered with the Chinese Clinical Trial Registry (registration no. ChiCTR-TRC-12002321).
| INTRODUC TI ON
Cervical cancer is the fourth most common cancer diagnosed in women worldwide. Of these, nearly 85% occur in low-and middleincome countries (LMIC), which causes considerable social and economic impact. 1 Concomitant cisplatin-based chemoradiotherapy followed by high dose rate (HDR) brachytherapy (BT) represents the standard of care in patients with tumors larger than 4 cm, that is, from stage Ib2 to stage IVa. 2 Brachytherapy is an integral component of definitive radiation for cervical cancer, 3, 4 and proper positioning of intracavitary applicators has been singled out as the most important prognostic factor in improving local control (LC) of disease. 5 The BT component of treatment can be undertaken using an intracavitary (IC), interstitial (IS), or hybrid (IC and IS) implant. The guidelines from the American Brachytherapy Society (ABS) recommend HDR ISBT for cervical cancer patients in certain clinical situations such as bulky lesions, a narrow vaginal apex, inability to enter the cervical os, extension to the lateral parametria or pelvic sidewall, and lower vaginal extension. 6 Compared to the ICBT technique, ISBT with special dosimetric advantages is more invasive and complex, involving individualized catheter placement and image guidance, and higher requirements for doctors and patients. Consequently, it is difficult to enable ISBT to be equally accessible nationwide. 6 To attempt to reach optimum dose distribution from ICBT for carcinoma of the uterine cervix with conditions such as narrow vaginal apex and lower vaginal extension in LMIC, we designed a single-channel applicator (China Patent no. 200710050108.1), wrapped with an oval-shield alloy around the source channel, which was modified from the traditional tandem applicator. The patented single-channel applicator effectively decreases the high-dose coverage on the anterior-posterior axis and has the same dose contributions to bladder and rectum points with Fletcher applicators (Figure 1 ). We speculated that this singlechannel applicator might also be useful for other patients who do not have narrow vagina and lower vaginal extension. As it has a simpler structure, this method could simplify implantation proce- Figure 2 . Patients in both groups were treated with concurrent cisplatin chemotherapy and external beam radiotherapy (EBRT) followed by HDR BT (not including IIa1).
A preliminary analysis was planned for when at least 150 patients had achieved a minimum follow-up of 2 years. A flow diagram of the progress of the trial is summarized in Figure 3 . 
| Patient eligibility criteria

| External beam radiotherapy
| Chemotherapy
The patients received cisplatin chemotherapy at a dose of 40 mg/m 
| Brachytherapy
Five to 6 fractions with a dose of 7 Gy per fraction of ICBT once a week were given to all patients after the third week of pelvic irradiation. Standard Fletcher applicators or the patented single-channel applicators were used according to the random number. A Foley's catheter was placed in the bladder and filled with 7 mL diluted contrast media. The vagina was packed with gauze to fix and increase the distance between the radiation source, and the rectum and bladder. In order to prevent the rotation of the applicator during treatment, a special rubber plug is applied to fix the depth of the single tube applicator. There is a direction mark in the tube that indicates the front and back direction of the lead, which should be consistent The Netherlands) for all patients. The doses to point A, the rectum, and the bladder were calculated according to ICRU 38 recommendations. 10 All patients were treated without sedation except 1 patient in the Fletcher applicator group.
| Follow-up and evaluation of toxicity
After completion of treatment, patients in both groups were followed up the first month after the end of treatment, then once every 3 months in the first 2 years, 6 months in the third and fifth years, and annually thereafter, alternating between a radiation oncologist and gynecology oncologist. At each visit, a complete history, clinical examination, and blood work, including a complete blood count and blood chemistry profile, were ob- To compare the 2 treatment groups, χ 2 analyses were used; Fisher's exact test was used for binary variables when sample sizes were small. SPSS software, version 17.0 (SPSS, Chicago, IL, USA), was used for all data analyses, and all P values were based on a 2-sided hypothesis. A value of P < 0.05 was considered statistically significant.
| RE SULTS
| Patient characteristics
Between Table 1 . The patients in 2 groups for preliminary analysis showed compatible clinical characteristics.
| Feasibility and acute adverse events
Two patients (2.8%) in the Fletcher group and 1 (1.3%) patient in the single-channel group did not receive concurrent chemotherapy.
Chemotherapy was given for 5 or more courses in 31 patients (43.7%) in the Fletcher group, and 26 patients (32.5%) in the single-channel group. The median number of chemotherapy cycles in both groups was 4, and the majority of reasons for delays in chemotherapy administration was grade 3-4 hematological toxicity. The response rate was 97.2%
in the Fletcher group, and 96.3% in the single-channel group. Table 2 summarizes the acute hematological toxicity and nonhematologic tox- and para-aortic radiotherapy because of para-aortic nodal metastasis.
| Follow-up outcomes
Up to October 2017, the median duration of follow-up was 40 months Two patients that were lost to follow-up in the Fletcher group had distant metastasis. b Four patients that were lost to follow-up in the single-channel group had local failure, and 1 patient had distant metastasis.
83.8% for the single-channel group (P = 0.369). The outcomes of the 2 groups of patients are listed in Table 3 . No grade 4 bladder complications were observed in the 2 groups.
| Late toxicity
The cumulative rate of grade 3 bladder complications was 2.8% for the Fletcher group and 1.3% for the single-channel group. No significant differences were identified for late radiation proctitis and cystitis between the 2 groups.
| D ISCUSS I ON
The main objective of radiation therapy is to deliver a precise dose of irradiation to a defined tumor volume while keeping the damage to surrounding healthy tissue as minimal as possible. This concept is especially important in the presence of surrounding dose-limiting organs, such as the rectum and bladder, in the treatment of gynecological cancers where initial EBRT is given to the whole pelvis.
Intracavitary BT offers the best possibility to decrease the dose to normal tissues while prescribing a curable dose to the target volume in gynecological cancers.
The dose distribution of an IC application depends on a number of parameters, such as the type, size, and geometry of the applicators, fixation procedures, packing technique, anatomical variations, and the prescription of reference points. 13 Image-guided BT in locally advanced cervix cancer has recently been introduced and shown to provide improvements in dose volume parameters, which allows changing the size and the shape of the classical pear-shaped isodose according to the target volume. 14 This improvement in target coverage and reduction in dose to critical organs has been shown to improve LC and decrease toxicities. 15 However, in many low-resource settings where 3D imaging, and in some cases 2D imaging, is not possible at the time of applicator placement, volumebased contouring is not realistic, only a 25% volume-based dose. 16 Thus, for these settings, a high-quality implant is mainly determined by the patient anatomy, tumor geometry, and the brachytherapist's experience. 6 In the absence of appropriate sedation and analgesia, which was unexpectedly found in many LMIC, 6, 16, 17 . 20 Therefore quality of implant colpostats is the most important issue for a standard ICBT. 21 If treatment with a single-channel intrauterine applicator was available with the same dose contributions as a 3-channel applicator, the BT implant would become simple and the uncertainty of the applicator geometrical arrangements would also be reduced.
For this goal, we designed a single-channel applicator, wrapped with an oval-shield alloy around the source channel, which was modified from the traditional tandem applicator. The oval-shield alloy is thin on the side and thick on the middle, which was intended to reduce the doses in the ventral and dorsal directions, thereby shielding the bladder base and the anterior wall of the rectum. Iridium-192 is a radiation source with lower gamma energy; the effective energy is approximately 384 keV and the half value layer is 3 mm in lead. So the shielding material can be very thin, but it does not affect the structure of the intrauterine applicator. 22 For its oval-shield alloy, the shape of the sagittal views of the reference dose distribution through point A was pear shape, as in the classical Manchester system. Enlarging the upper part of the pear shape isodose envelope can increase the dose of point A, but the dose of the rectum and bladder will not increase as sharply as a single tandem applicator.
A phase I study found that, of 20 patients with cervical carcinoma treated with the patented single-channel applicator, 15 (75.0%)
Fletcher, % (n); n = 71
Single-channel, % (n); n = 80 24 In addition, the EQD2 to point A ranged from 80.0-90.0 Gy (median, 90.0 Gy) in the present study, and only 4 patients had 5 brachytherapy insertions (EQD2, 80 Gy). This means that as high as 97.3% of patients in our study accepted a total EQD2 of 90 Gy to point A. But because of the 1-week BT schedule, the median total treatment time was more than 8 weeks, which was recommended by ABS. 24 The severity of acute treatment-related toxicities was similar in the Fletcher group and the single-channel group. Thirty-five (49.3%) patients in the Fletcher group and 42 (52.5%) in the single-channel group had acute grade 3-4 hematologic toxicity, which was higher than in other reports. 25 No grade 4 acute nonhematologic toxicity was observed in the 2 groups. Because of the high treatment-related hematologic toxicity, only a small number of patients received 5 or more courses of concurrent cisplatin chemotherapy. The acute rectal/bladder toxicity was comparable with earlier reports. 25 In order to reduce the influence of artificial factors, this study gave the majority of patients (97.3%) the same high dosing parameters (EQD2, 90 Gy) and the late rectal/bladder toxicities were the focus of our observation. The cumulative rate of grade 1-2 rectal/ bladder complications for all patients was higher than another study; nevertheless, the cumulative rate of grade 3-4 rectal/bladder (1.3%-2.8%) complications was acceptable, compared with the other reports of 6%-23.3% late grade 3 and 4 toxicities. 25 No significant differences were observed for late radiation proctitis or cystitis between the 2 groups.
In conclusion, the preliminary results of the present study suggest that the patented single-channel IC applicator might be able to provide protection for the rectum and bladder and seems to have the same clinical efficacy as the standard Fletcher-type 3-channel applicator in HDR BT for carcinoma of the cervix. Further studies are needed to assess long-term outcomes and associated toxicities.
ACK N OWLED G M ENTS
This work was supported by the Science and Technology Department, Sichuan Province (LY-86).
CO N FLI C T O F I NTE R E S T
The authors have no conflict of interests to declare.
O RCI D
Dan Li http://orcid.org/0000-0001-5194-400X
